Ribosome-Directed Therapies in Cancer

Creative Commons License

Temaj G., Chichiarelli S., Eufemi M., Altieri F., Hadziselimovic R., Farooqi A. A., ...More

BIOMEDICINES, vol.10, no.9, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 10 Issue: 9
  • Publication Date: 2022
  • Doi Number: 10.3390/biomedicines10092088
  • Journal Name: BIOMEDICINES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, BIOSIS, Directory of Open Access Journals
  • Keywords: ribosome, cancer, target drugs, rRNA and tRNA inhibition, RNA-POLYMERASE I, PEPTIDYL TRANSFERASE CENTER, C-MYC, MEGESTROL-ACETATE, PROTEIN-SYNTHESIS, STRUCTURAL BASIS, PROSTATE-CANCER, NONCODING RNAS, TRANSLATIONAL CONTROL, INACTIVATING PROTEIN
  • Istanbul University Affiliated: Yes

Abstract

The human ribosomes are the cellular machines that participate in protein synthesis, which is deeply affected during cancer transformation by different oncoproteins and is shown to provide cancer cell proliferation and therefore biomass. Cancer diseases are associated with an increase in ribosome biogenesis and mutation of ribosomal proteins. The ribosome represents an attractive anti-cancer therapy target and several strategies are used to identify specific drugs. Here we review the role of different drugs that may decrease ribosome biogenesis and cancer cell proliferation.